Bernstein: Sichuan Kelun-Biotech Biopharmaceutical-B (06990.HK) Achieves Positive Progress in Lung Cancer Research; Maintains "Outperform" Rating with Target Price of HK$526

Zhitong Finance APP has learned that Bernstein issued a research report maintaining a "Outperform" rating and a target price of HK$526 for Kelun-Biotech-B (06990.HK). The bank noted that the OptiTROP-Lung06 and OptiTROP-Lung04 lung cancer study results announced by the company during the European Society for Medical Oncology (ESMO) Annual Congress both achieved positive progress, with both studies demonstrating significant survival benefits, further improving the prospects of the TROP2 ADC drug jointly developed by Kelun-Biotech and Merck in global clinical trials.